Benzinga | Feb 2, 2021 06:35AM EST

SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $250

SVB Leerink analyst Geoff Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform and lowers the price target from $257 to $250.